- NCIt
- C4242
Loading cancer entity…
Loading cancer entity…
Clinical trials
461 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04655144 | Dexamethasone for Post Uterine Artery Embolization Pain(Dex-Fib) | completed | Phase 3 | 42 | University of MiamiOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05440383 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | completed | Phase 3 | 287 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03751124 | Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 229 | Myovant Sciences GmbHINDUSTRY | 8 | Jun 25, 2024 | clinicaltrials |
| NCT03412890 | LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 477 | Myovant Sciences GmbHINDUSTRY | 9 | May 9, 2024 | clinicaltrials |
| NCT00133705 | Trial of Mifepristone for Fibroids | completed | Phase 3 | 70 | University of RochesterOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)(ENLIVEN) | completed | Phase 3 | 120 | Daiichi SankyoINDUSTRY | 12 | May 11, 2022 | clinicaltrials |
| NCT03103087 | LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 382 | Myovant Sciences GmbHINDUSTRY | 8 | Apr 20, 2022 | clinicaltrials |
| NCT03049735 | LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 388 | Myovant Sciences GmbHINDUSTRY | 6 | Apr 19, 2022 | clinicaltrials |
| NCT02925494 | An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | completed | Phase 3 | 433 | AbbVieINDUSTRY | 3 | Jul 13, 2021 | clinicaltrials |
| NCT03070899 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 1) | completed | Phase 3 | 526 | ObsEva SAINDUSTRY | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT02189083 | Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids | completed | Phase 3 | 78 | The University of Hong KongOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT02147158 | A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas | completed | Phase 3 | 432 | AllerganINDUSTRY | 2 | Jun 4, 2019 | clinicaltrials |
| NCT02147197 | A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas | completed | Phase 3 | 157 | AllerganINDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02634931 | Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex | completed | Phase 3 | 94 | NobelpharmaINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00365989 | MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication | completed | Phase 3 | 50 | InSightecINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT00295217 | MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation | completed | Phase 3 | 15 | InSightecINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01715597 | Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma | completed | Phase 3 | 50 | Seoul National University HospitalOTHER | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02635789 | Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | completed | Phase 3 | 62 | NobelpharmaINDUSTRY | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01156857 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIII) | completed | Phase 3 | 209 | PregLem SAINDUSTRY | 4 | Jan 15, 2016 | clinicaltrials |
| NCT01252069 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) | completed | Phase 3 | 132 | PregLem SAINDUSTRY | 4 | Jan 13, 2016 | clinicaltrials |
| NCT01642472 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLext2) | completed | Phase 3 | 64 | PregLem SAINDUSTRY | 4 | Jan 8, 2016 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT02061657 | Impact of Misoprostol on Blood Loss In Myomectomy Operations | completed | Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Aug 12, 2014 | clinicaltrials |
| NCT01581944 | Gonadotropin-releasing Hormone Agonist Prior to Myomectomy | completed | Phase 3 | 68 | Mt. Hope Maternity HospitalOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00712595 | Mifepristone for Treatment of Uterine Fibroids(Mifemyo) | completed | Phase 2 / Phase 3 | 200 | Mediterranea Medica S. L.OTHER | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00152256 | A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids | completed | Phase 3 | 239 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00152269 | Treatment of Uterine Fibroids With Asoprisnil(J867) | completed | Phase 3 | 475 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156195 | Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids | completed | Phase 3 | 523 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156208 | Safety of Treatment of Uterine Fibroids With Asoprisnil | completed | Phase 3 | 166 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00160381 | A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids | completed | Phase 3 | 432 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156156 | Study of Asoprisnil in the Treatment of Uterine Fibroids. | completed | Phase 3 | 149 | AbbottINDUSTRY | 0 | May 28, 2008 | clinicaltrials |
| NCT00100191 | Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids | completed | Phase 3 | 120 | ZonMw: The Netherlands Organisation for Health Research and DevelopmentOTHER | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jan 7, 2026source: clinicaltrials